# Nasdaq Chaos: Split Drama & Market Mayhem! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-08-07T14:00:00.191Z Source: https://newsyai.com/edition/68afc80f-9586-4e9f-b0a1-91887f8d03b5 Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Nasdaq’s Reverse-Split Shitshow: Online Hustlers, Asian Capital Grifters & Chinese Pharma Repeat Offenders – August 7, 2026 Edition!** Futures mixed (Dow still comatose, Nasdaq chasing that AI/chip boner from yesterday, crude oil playing volatility peek-a-boo). The MVLS $5M rule drama is on pause per the SEC stay, but repeat-split offenders and nano-cap desperation keep the meat grinder spinning. Yesterday’s lidar stiffies, blood filters, and data hustlers? Old news. Fresh carnage today: extreme-ratio compliance plays where bulls sniff post-split pops and float shrinkage, while bears smell chronic dilution, zero traction, and delisting guillotines.[[1]](https://finance.yahoo.com/calendar/splits/) ### 1) GRNQ (Greenpro Capital Corp): “1-for-10 Capital Grifter Stiffy vs. Asian Hustle & Dilution Gangbang” **Why it’s loud** Savage 1-for-10 reverse split just hit (effective Aug 6, trading split-adjusted). Kuala Lumpur-based “capital” play chasing Nasdaq $1 bid compliance amid the usual microcap squeeze.[[2]](https://www.stocktitan.net/sec-filings/GRNQ/8-k-greenpro-capital-corp-reports-material-event-71e02864b9b7.html) **Bull case (compliance rocket + capital erection)** 10x ratio + any “Asian growth narrative” whisper = $1–4+ rip. Shrunken float turns noise into rocket fuel—ride the hustle fantasy, degens! **Bear case (dilution gangbang & split limp encore)** 10x screams capital hunger, zero proven commercial wins, brutal competition and governance red flags = sub-penny cemetery. Short the fade before the next offering tsunami! **My take, first principles (real capital signal vs. listing cancer)** Genuine financial services IP in emerging markets offers short-term narrative juice, but cash burn reality, dilution history, and stricter Nasdaq rules scream unsustainable trap. Narrative lottery with moonshot potential. Scalp the spunk? **$0.08–2.10** range, **$0.48C** capital pump—**P$0.07** dilution fade. ### 2) ONFO (Onfolio Holdings): “1-for-50 Online Business Boner vs. Compliance Hangover & Cash Flow Mirage” **Why it’s loud** Insane 1-for-50 reverse split coming Aug 10 to claw back Nasdaq compliance. Owner-operator of “cash-generative” online businesses—bulls eye any digital rebound with the post-split float; bears hammer the desperation ratio and execution risks.[[3]](https://www.stocktitan.net/news/ONFO/onfolio-holdings-announces-1-for-50-reverse-stock-split-to-regain-7esv4hb9s3fq.html) **Bull case (compliance stiffy + digital erection)** 50x ratio + volume pop + any online hustle narrative = $1–5+ rip. Ride the cash-flow fantasy, apes—tiny float turns noise into rocket fuel! **Bear case (dilution gangbang & split limp encore)** 50x screams capital hunger, questionable “cash-generative” claims, brutal competition = sub-$0.05 graveyard. Short the fade before the next offering tsunami! **My take, first principles (real online signal vs. listing cancer)** Genuine digital asset IP offers short-term hype juice in the online economy, but cash burn reality, dilution history, and stricter Nasdaq rules scream unsustainable trap. Sector lottery at best. Scalp it? **$0.06–1.90** range, **$0.45C** hustle pump—**P$0.06** dilution fade. ### 3) SXTC (China SXT Pharmaceuticals): “1-for-80 Pharma Repeat-Offender Stiffy vs. Regulatory Minefield & Dilution Death Spiral” **Why it’s loud** Monstrous 1-for-80 reverse split effective Aug 10—another in a long line of splits for this Chinese pharma play. Bulls chase any drug pipeline whisper with the post-split float; bears hammer governance, regulatory risks, and serial dilution.[[4]](https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-558) **Bull case (compliance rocket + pharma erection)** 80x ratio + volume spike + any China healthcare tailwind = $1–4+ rip. Ride the drug fantasy, degens—shrunken float turns noise into rocket fuel! **Bear case (dilution gangbang & split limp encore)** 80x screams capital hunger, zero consistent commercial traction, brutal China regulatory and competition risks = sub-penny cemetery. Short the fade before the next offering tsunami! **My take, first principles (real pharma signal vs. listing cancer)** Genuine drug development IP offers short-term narrative juice in healthcare, but cash burn reality, dilution history, repeated splits, and stricter Nasdaq rules scream unsustainable trap. Narrative lottery with moonshot potential. Scalp the spunk? **$0.05–1.70** range, **$0.42C** pharma pump—**P$0.05** dilution fade. **Tape-Side Tactics (GRNQ Capital Mayhem, ONFO Hustle Grind & SXTC Pharma Chaos – August 7 Edition)** - **GRNQ**: **$0.08–2.10** stiffy; **$0.48C** capital pump, **P$0.07** fade. - **ONFO**: **$0.06–1.90** stiffy; **$0.45C** hustle pump, **P$0.06** fade. - **SXTC**: **$0.05–1.70** stiffy; **$0.42C** pharma pump, **P$0.05** fade. MVLS pressure and reverse-split rules still tightening the noose amid crude cock-up and micro-madness. Balls-deep DYOR, NFA, degens duck the dilutions! **Sources** (for tracking every claim above): - Reverse splits & reactions: Nasdaq Trader Equity Corporate Actions Alerts, Yahoo Finance Stock Splits Calendar, StockTitan (Aug 2026 data). - Company announcements & details: Company IR sites, SEC filings via Yahoo Finance/StockTitan. - Nasdaq reverse-split rule changes & MVLS: SEC filings, Nasdaq Listing Rules (2026 updates). - Broader microcap/premarket context & volatility: Yahoo Finance, recent market data.